These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32253095)

  • 21. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.
    Fridman JS; Scherle PA; Collins R; Burn TC; Li Y; Li J; Covington MB; Thomas B; Collier P; Favata MF; Wen X; Shi J; McGee R; Haley PJ; Shepard S; Rodgers JD; Yeleswaram S; Hollis G; Newton RC; Metcalf B; Friedman SM; Vaddi K
    J Immunol; 2010 May; 184(9):5298-307. PubMed ID: 20363976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure activity optimization of 6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazines as Jak1 kinase inhibitors.
    Friedman M; Frank KE; Aguirre A; Argiriadi MA; Davis H; Edmunds JJ; George DM; George JS; Goedken E; Fiamengo B; Hyland D; Li B; Murtaza A; Morytko M; Somal G; Stewart K; Tarcsa E; Van Epps S; Voss J; Wang L; Woller K; Wishart N
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4399-404. PubMed ID: 26372653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors.
    Liang J; van Abbema A; Balazs M; Barrett K; Berezhkovsky L; Blair W; Chang C; Delarosa D; DeVoss J; Driscoll J; Eigenbrot C; Ghilardi N; Gibbons P; Halladay J; Johnson A; Kohli PB; Lai Y; Liu Y; Lyssikatos J; Mantik P; Menghrajani K; Murray J; Peng I; Sambrone A; Shia S; Shin Y; Smith J; Sohn S; Tsui V; Ultsch M; Wu LC; Xiao Y; Yang W; Young J; Zhang B; Zhu BY; Magnuson S
    J Med Chem; 2013 Jun; 56(11):4521-36. PubMed ID: 23668484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of rheumatoid arthritis.
    Yin Y; Chen CJ; Yu RN; Shu L; Wang ZJ; Zhang TT; Zhang DY
    Bioorg Chem; 2020 May; 98():103720. PubMed ID: 32171982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of azabenzimidazoles as potent JAK1 selective inhibitors.
    Vasbinder MM; Alimzhanov M; Augustin M; Bebernitz G; Bell K; Chuaqui C; Deegan T; Ferguson AD; Goodwin K; Huszar D; Kawatkar A; Kawatkar S; Read J; Shi J; Steinbacher S; Steuber H; Su Q; Toader D; Wang H; Woessner R; Wu A; Ye M; Zinda M
    Bioorg Med Chem Lett; 2016 Jan; 26(1):60-7. PubMed ID: 26614408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design of a peptide inhibitor of tyrosine kinase 2.
    Works MG; Song B; Kibler P; Tanga MJ; Galande AK; D'Andrea A
    Protein Pept Lett; 2014 May; 21(5):419-25. PubMed ID: 24304386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.
    Labadie S; Dragovich PS; Barrett K; Blair WS; Bergeron P; Chang C; Deshmukh G; Eigenbrot C; Ghilardi N; Gibbons P; Hurley CA; Johnson A; Kenny JR; Kohli PB; Kulagowski JJ; Liimatta M; Lupardus PJ; Mendonca R; Murray JM; Pulk R; Shia S; Steffek M; Ubhayakar S; Ultsch M; van Abbema A; Ward S; Zak M
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7627-33. PubMed ID: 23107482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors.
    Grimster NP; Anderson E; Alimzhanov M; Bebernitz G; Bell K; Chuaqui C; Deegan T; Ferguson AD; Gero T; Harsch A; Huszar D; Kawatkar A; Kettle JG; Lyne P; Read JA; Rivard Costa C; Ruston L; Schroeder P; Shi J; Su Q; Throner S; Toader D; Vasbinder M; Woessner R; Wang H; Wu A; Ye M; Zheng W; Zinda M
    J Med Chem; 2018 Jun; 61(12):5235-5244. PubMed ID: 29856615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.
    Menet CJ; Fletcher SR; Van Lommen G; Geney R; Blanc J; Smits K; Jouannigot N; Deprez P; van der Aar EM; Clement-Lacroix P; Lepescheux L; Galien R; Vayssiere B; Nelles L; Christophe T; Brys R; Uhring M; Ciesielski F; Van Rompaey L
    J Med Chem; 2014 Nov; 57(22):9323-42. PubMed ID: 25369270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fragment-Based Discovery of Pyrazolopyridones as JAK1 Inhibitors with Excellent Subtype Selectivity.
    Hansen BB; Jepsen TH; Larsen M; Sindet R; Vifian T; Burhardt MN; Larsen J; Seitzberg JG; Carnerup MA; Jerre A; Mølck C; Lovato P; Rai S; Nasipireddy VR; Ritzén A
    J Med Chem; 2020 Jul; 63(13):7008-7032. PubMed ID: 32462873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Revisiting Structure-activity Relationships: Unleashing the potential of selective Janus kinase 1 inhibitors.
    Shan M; Zhao X; Sun P; Qu X; Cheng G; Qin LP
    Bioorg Chem; 2024 Aug; 149():107506. PubMed ID: 38833989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis.
    Page KM; Suarez-Farinas M; Suprun M; Zhang W; Garcet S; Fuentes-Duculan J; Li X; Scaramozza M; Kieras E; Banfield C; Clark JD; Fensome A; Krueger JG; Peeva E
    J Invest Dermatol; 2020 Aug; 140(8):1546-1555.e4. PubMed ID: 31972249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery and Biological Evaluation of
    Park E; Lee SJ; Moon H; Park J; Jeon H; Hwang JS; Hwang H; Hong KB; Han SH; Choi S; Kang S
    J Med Chem; 2021 Jan; 64(2):958-979. PubMed ID: 33428419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of (2
    Su Q; Banks E; Bebernitz G; Bell K; Borenstein CF; Chen H; Chuaqui CE; Deng N; Ferguson AD; Kawatkar S; Grimster NP; Ruston L; Lyne PD; Read JA; Peng X; Pei X; Fawell S; Tang Z; Throner S; Vasbinder MM; Wang H; Winter-Holt J; Woessner R; Wu A; Yang W; Zinda M; Kettle JG
    J Med Chem; 2020 May; 63(9):4517-4527. PubMed ID: 32297743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic treatment of a novel selective JAK3/JAK1/TBK1 inhibitor, CS12192, in rat and mouse models of rheumatoid arthritis.
    Shan S; Zhou Y; Yu J; Yang Q; Pan D; Wang Y; Li L; Zhu J; Zhang Y; Huang S; Li Z; Ning Z; Xin L; Lu X
    Int Immunopharmacol; 2019 Dec; 77():105914. PubMed ID: 31634789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.
    Kulagowski JJ; Blair W; Bull RJ; Chang C; Deshmukh G; Dyke HJ; Eigenbrot C; Ghilardi N; Gibbons P; Harrison TK; Hewitt PR; Liimatta M; Hurley CA; Johnson A; Johnson T; Kenny JR; Bir Kohli P; Maxey RJ; Mendonca R; Mortara K; Murray J; Narukulla R; Shia S; Steffek M; Ubhayakar S; Ultsch M; van Abbema A; Ward SI; Waszkowycz B; Zak M
    J Med Chem; 2012 Jun; 55(12):5901-21. PubMed ID: 22591402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 4-Amino-pyrrolopyridine-5-carboxamide: a novel scaffold for JAK1-selective inhibitors.
    Shin H; Kim MK; Chong Y
    Chem Pharm Bull (Tokyo); 2014; 62(3):217-20. PubMed ID: 24583775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TYK2: an emerging therapeutic target in rheumatic disease.
    Morand E; Merola JF; Tanaka Y; Gladman D; Fleischmann R
    Nat Rev Rheumatol; 2024 Apr; 20(4):232-240. PubMed ID: 38467779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of 3-(4-(2-((1
    Zhang C; Qi W; Li Y; Tang M; Yang T; Liu K; Chen Y; Deng D; Xiang M; Chen L
    J Med Chem; 2021 Feb; 64(4):1966-1988. PubMed ID: 33593051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of WO-2013040863, WO-2013041042 and WO-2013043962. Selective JAK1 inhibitors based on a 3-aminopyrazole-4-carboxamide scaffold.
    Norman P
    Expert Opin Ther Pat; 2014 Feb; 24(2):231-7. PubMed ID: 24261748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.